Recent Updates — IOVA
Iovance Biotherapeutics announced updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial for lifileucel in previously treated non-squamous metastatic non-small-cell lung cancer. The data showed a 24.6% objective response rate (ORR) across 69 patients, consistent with prior reports. A retrospective analysis identified a biomarker-enriched subgroup defined by KRAS wild-type status, HER2 wild-type status, and smoking history that achieved a 59.1% ORR. The company plans to initiate POSILITY, a prospective biomarker-enriched study with registrational intent, in November 2026. These findings support the planned submission of a supplemental Biologics License Application (sBLA) for lifileucel in non-squamous mNSCLC in 2027. Iovance Biotherapeutics is a commercial biotechnology company developing and delivering tumor infiltrating lymphocyte cell therapies for cancer.
Iovance Biotherapeutics updated its corporate presentation on October 5, 2026, revealing an increase in full-year 2026 revenue guidance to a range of $410 million to $420 million. This midpoint represents approximately $55 million, or roughly 15%, above the previous guidance range of $350 million to $370 million. The company also highlighted that second-quarter 2026 revenue exceeded its prior guidance by more than 10%. Iovance Biotherapeutics is a biotechnology company specializing in tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors.
Iovance Biotherapeutics, Inc. raised its full year 2026 total revenue guidance to $410–$420 million on September 29, 2026. This new range represents a $55 million increase at the midpoint from the previous estimate of $350–$370 million, implying nearly 60% annual growth driven by strong U.S. demand for Amtagvi and Proleukin. The company reported record second quarter 2026 product revenue of $99.3 million and expects to expand its authorized treatment center network to at least 110 sites by year-end. Iovance Biotherapeutics operates in the biotechnology industry, innovating and delivering tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors.
Iovance Biotherapeutics reported second quarter 2026 financial results, announcing record total revenue of $99.3 million and a gross margin of 56%, driven by strong U.S. Amtagvi demand which reached approximately $91 million. The company is reviewing its full-year 2026 revenue guidance of $350 million to $370 million in light of these results, with an update expected in the third quarter. Additionally, the FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas based on positive early data from the registrational SARATOGA trial. The company holds approximately $304 million in cash as of June 30, 2026. Iovance Biotherapeutics operates in the biotechnology industry, specializing in developing and commercializing tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors.